CD34+ myeloma cells with self-renewal activities are therapy-resistant and persist as MRD in cell cycle quiescence-Reference-Cited by-同舟云学术

CD34+ myeloma cells with self-renewal activities are therapy-resistant and persist as MRD in cell cycle quiescence

Published:2022-02-08 Issue:3 Volume:115 Page:336-349
ISSN:0925-5710
Container-title:International Journal of Hematology
language:en
Short-container-title:Int J Hematol

Author:

Serizawa Kentaro,Tanaka Hirokazu^ORCID,Ueda Takeshi,Fukui Ayano,Kakutani Hiroaki,Taniguchi Takahide,Inoue Hiroaki,Kumode Takahiro,Taniguchi Yasuhiro,Rai Shinya,Hirase Chikara,Morita Yasuyoshi,Espinoza J. Luis,Tatsumi Yoichi,Ashida Takashi,Matsumura Itaru

Publisher

Springer Science and Business Media LLC

Subject

Hematology

Link

https://link.springer.com/content/pdf/10.1007/s12185-021-03261-0.pdf

Reference52 articles.

1. Rajkumar SV, Dimopoulos MA, Palumbo A, Blade J, Merlini G, Mateos MV, et al. International myeloma working group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 2014;15(12):e535-548.

2. Landgren O, Iskander K. Modern multiple myeloma therapy: deep, sustained treatment response and good clinical outcomes. J Intern Med. 2017;281(4):365–82.

3. Kumar S, Paiva B, Anderson KC, Durie B, Landgren O, Moreau P, et al. International myeloma working group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol. 2016;17(8):e328-346.

4. Munshi NC, Avet-Loiseau H, Rawstron AC, Owen RG, Child JA, Thakurta A, et al. Association of minimal residual disease with superior survival outcomes in patients with multiple myeloma: a meta-analysis. JAMA Oncol. 2017;3(1):28–35.

5. Perrot A, Lauwers-Cances V, Corre J, Robillard N, Hulin C, Chretien ML, et al. Minimal residual disease negativity using deep sequencing is major prognostic factor in multiple myeloma. Blood. 2018;132(23):2456–64.

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Targeting cancer stem cells in multiple myeloma;Trends in Cancer;2024-08

2. Molecular and immunological mechanisms of clonal evolution in multiple myeloma;Frontiers in Immunology;2023-09-06